GMED vs. STE, PODD, BAX, HOLX, MASI, TFX, ITGR, ATEC, ATRC, and IART
Should you be buying Globus Medical stock or one of its competitors? The main competitors of Globus Medical include STERIS (STE), Insulet (PODD), Baxter International (BAX), Hologic (HOLX), Masimo (MASI), Teleflex (TFX), Integer (ITGR), Alphatec (ATEC), AtriCure (ATRC), and Integra LifeSciences (IART). These companies are all part of the "health care equipment" industry.
Globus Medical vs.
Globus Medical (NYSE:GMED) and STERIS (NYSE:STE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, community ranking, analyst recommendations and valuation.
95.2% of Globus Medical shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 18.5% of Globus Medical shares are held by insiders. Comparatively, 1.1% of STERIS shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Globus Medical received 231 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 67.21% of users gave Globus Medical an outperform vote while only 59.38% of users gave STERIS an outperform vote.
Globus Medical has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, STERIS has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.
In the previous week, STERIS had 14 more articles in the media than Globus Medical. MarketBeat recorded 22 mentions for STERIS and 8 mentions for Globus Medical. STERIS's average media sentiment score of 0.40 beat Globus Medical's score of 0.27 indicating that STERIS is being referred to more favorably in the news media.
Globus Medical presently has a consensus target price of $94.00, suggesting a potential upside of 53.71%. STERIS has a consensus target price of $263.83, suggesting a potential upside of 9.21%. Given Globus Medical's higher possible upside, equities analysts plainly believe Globus Medical is more favorable than STERIS.
STERIS has a net margin of 8.66% compared to Globus Medical's net margin of 4.09%. STERIS's return on equity of 13.91% beat Globus Medical's return on equity.
STERIS has higher revenue and earnings than Globus Medical. STERIS is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.
Summary
STERIS beats Globus Medical on 10 of the 18 factors compared between the two stocks.
Get Globus Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Globus Medical Competitors List
Related Companies and Tools
This page (NYSE:GMED) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy GMED Stock Free GMED Stock Alerts